HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $4.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Nuvation Bio (NYSE:NUVB) and maintained a price target of $4.5.
November 22, 2023 | 11:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns reaffirmed a Buy rating on Nuvation Bio with a price target of $4.5.
The reiteration of a Buy rating and the maintenance of a price target by a reputable analyst like Robert Burns could lead to increased investor confidence in Nuvation Bio, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100